Transcode Therapeutics Inc (RNAZ) - Total Assets
Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) holds total assets worth $5.23 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Transcode Therapeutics Inc's book value for net asset value and shareholders' equity analysis.
Transcode Therapeutics Inc - Total Assets Trend (2018–2024)
This chart illustrates how Transcode Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Transcode Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Transcode Therapeutics Inc's total assets of $5.23 Billion consist of 97.2% current assets and 2.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Transcode Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Transcode Therapeutics Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Transcode Therapeutics Inc's current assets represent 97.2% of total assets in 2024, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 79.7% of total assets in 2024, down from 99.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Transcode Therapeutics Inc Competitors by Total Assets
Key competitors of Transcode Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Transcode Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.60 | 1.58 | 2.05 |
| Quick Ratio | 1.60 | 1.58 | 2.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.78 Billion | $1.33 Million | $426.35K |
Transcode Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Transcode Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.94 |
| Latest Market Cap to Assets Ratio | 0.98 |
| Asset Growth Rate (YoY) | 41.1% |
| Total Assets | $7.29 Million |
| Market Capitalization | $7.18 Million USD |
Valuation Analysis
Near Book Valuation: The market values Transcode Therapeutics Inc's assets close to their book value (0.98x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Transcode Therapeutics Inc's assets grew by 41.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Transcode Therapeutics Inc (2018–2024)
The table below shows the annual total assets of Transcode Therapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $7.29 Million | +41.10% |
| 2023-12-31 | $5.17 Million | -31.87% |
| 2022-12-31 | $7.59 Million | -66.92% |
| 2021-12-31 | $22.94 Million | +2073.50% |
| 2020-12-31 | $1.06 Million | +386.92% |
| 2019-12-31 | $216.74K | +0.98% |
| 2018-12-31 | $214.65K | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its… Read more